CEL-SCI CORPORATION Retained Earnings
CEL-SCI CORPORATION (CVM) had Retained Earnings of -$556.03 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-14
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$556.03M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$550.36M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$544.89M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$539.42M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$556.03M 10-Q · filed 2026-08-14 | |
| 2026-03-31 | -$550.36M 10-Q · filed 2026-05-15 | |
| 2025-12-31 | -$544.89M 10-Q · filed 2026-02-17 | |
| 2025-09-30 | -$539.42M 10-Q · filed 2026-08-14 | |
| 2025-06-30 | -$533.32M 10-Q · filed 2025-08-14 | |
| 2025-03-31 | -$527.66M 10-Q · filed 2025-05-14 | |
| 2024-12-31 | -$521.08M 10-Q · filed 2025-02-14 | |
| 2024-09-30 | -$514.01M 10-K · filed 2025-12-29 | |
| 2024-06-30 | -$507.90M 10-Q · filed 2024-08-14 | |
| 2024-03-31 | -$501.05M 10-Q · filed 2024-05-15 | |
| 2023-12-31 | -$493.80M 10-Q · filed 2024-02-14 | |
| 2023-09-30 | -$487.09M 10-K · filed 2025-01-13 | |
| 2023-06-30 | -$479.46M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | -$471.09M 10-Q · filed 2023-05-12 | |
| 2022-12-31 | -$462.75M 10-Q · filed 2023-02-14 | |
| 2022-09-30 | -$454.90M 10-K · filed 2023-12-21 | |
| 2022-06-30 | -$446.44M 10-Q · filed 2022-08-12 | |
| 2022-03-31 | -$436.80M 10-Q · filed 2022-05-13 | |
| 2021-12-31 | -$426.98M 10-Q · filed 2022-02-11 | |
| 2021-09-30 | -$418.20M 10-K · filed 2022-12-27 | |
| 2021-06-30 | -$409.99M 10-Q · filed 2021-08-13 | |
| 2021-03-31 | -$401.05M 10-Q · filed 2021-05-17 | |
| 2020-12-31 | -$389.77M 10-Q · filed 2021-02-12 | |
| 2020-09-30 | -$381.84M 10-K · filed 2021-12-21 | |
| 2020-06-30 | -$376.46M 10-Q/A · filed 2020-12-31 | -$378.33M 10-Q/A · filed 2020-08-11 |
| 2020-03-31 | -$366.18M 10-Q/A · filed 2020-12-30 | -$368.11M 10-Q · filed 2020-05-08 |
| 2019-12-31 | -$357.11M 10-Q/A · filed 2020-12-30 | -$359.10M 10-Q · filed 2020-02-10 |
| 2019-09-30 | -$353.73M 10-Q/A · filed 2020-12-31 | |
| 2019-06-30 | -$348.88M 10-Q · filed 2019-08-14 | |
| 2019-03-31 | -$336.79M 10-Q · filed 2019-05-14 | |
| 2018-12-31 | -$330.35M 10-Q · filed 2019-02-14 | |
| 2018-09-30 | -$331.59M 10-K/A · filed 2019-12-23 | |
| 2018-06-30 | -$316.66M 10-Q · filed 2018-08-14 | |
| 2018-03-31 | -$310.65M 10-Q · filed 2018-05-15 | |
| 2017-12-31 | -$305.94M 10-Q · filed 2018-02-12 | |
| 2017-09-30 | -$299.75M 10-K · filed 2018-12-19 | |
| 2017-06-30 | -$294.76M 10-Q/A · filed 2017-12-11 | -$294.99M 10-Q · filed 2017-08-09 |
| 2017-03-31 | -$290.30M 10-Q/A · filed 2017-12-11 | -$290.54M 10-Q · filed 2017-05-10 |
| 2016-12-31 | -$281.87M 10-Q/A · filed 2017-12-11 | -$282.13M 10-Q · filed 2017-02-09 |
| 2016-09-30 | -$285.39M 10-K · filed 2017-12-29 | -$285.67M 10-K · filed 2016-12-15 |
| 2016-06-30 | -$284.55M 10-Q · filed 2016-08-09 | |
| 2016-03-31 | -$280.70M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | -$271.86M 10-Q · filed 2016-02-09 | |
| 2015-09-30 | -$273.88M 10-K/A · filed 2017-12-11 | -$274.20M 10-K · filed 2015-12-11 |
| 2015-06-30 | -$264.36M 10-Q · filed 2015-08-07 | |
| 2015-03-31 | -$259.93M 10-Q · filed 2015-05-08 | |
| 2014-12-31 | -$247.37M 10-Q · filed 2015-02-06 | |
| 2014-09-30 | -$239.19M 10-K/A · filed 2017-12-11 | -$239.53M 10-K · filed 2014-12-23 |
| 2014-06-30 | -$232.31M 10-Q · filed 2014-08-08 | |
| 2014-03-31 | -$229.86M 10-Q · filed 2014-05-12 | |
| 2013-12-31 | -$216.49M 10-Q · filed 2014-02-10 | |
| 2013-09-30 | -$211.83M 10-K/A · filed 2017-12-11 | -$212.16M 10-K · filed 2013-12-27 |
| 2013-06-30 | -$210.46M 10-Q · filed 2013-08-09 | |
| 2013-03-31 | -$206.01M 10-Q · filed 2013-05-10 | |
| 2012-12-31 | -$205.30M 10-Q · filed 2013-02-08 | |
| 2012-09-30 | -$202.99M 10-K · filed 2013-12-27 | |
| 2012-06-30 | -$200.42M 10-Q · filed 2012-08-09 | |
| 2012-03-31 | -$199.59M 10-Q · filed 2012-05-10 | |
| 2011-12-31 | -$191.09M 10-Q · filed 2012-02-09 | |
| 2011-09-30 | -$187.51M 10-K · filed 2012-12-14 | |
| 2011-06-30 | -$185.19M 10-Q · filed 2011-08-09 | |
| 2010-09-30 | -$161.80M 10-K · filed 2011-12-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |